Nanoparticledrug delivery enhances the cytotoxicity of hydrophobic–hydrophilic drug conjugates

Aryal, Santosh; Hu, Che Ming Jack; Fu, Victoria; Zhang, Liangfang

doi:10.1039/c1jm13834k

Cited by 71 publications

(42 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was hypothesized that applying ADD–DOX (M) to cells might lead to a much higher inhibitory effect than application of free ADD–DOX conjugates, because ADD–DOX (M) would exist within endolysosomes but free ADD–DOX might directly diffuse into the cytoplasm. 21 This matched well with the results shown in Fig. 7.…”

Section: Resultssupporting

confidence: 91%

Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells

Cuixia

et al. 2015

J. Mater. Chem. B

View full text Add to dashboard Cite

Combination therapy has been regarded as a potent strategy to overcome multidrug resistance (MDR). In this study, we adopt Adjudin (ADD), a mitochondria inhibitor, and Doxorubicin (DOX), a common chemo-drug, to treat drug-resistant cancer cells (MCF-7/ADR) in combination. Given the different physico-chemical properties of ADD and DOX, we develop a novel drug formulation (ADD–DOX (M)) by integrating drug conjugation and nanocarrier approaches to realize the co-delivery of the two drugs. We demonstrate the conjugation of ADD and DOX via formation of an acid-sensitive hydrazone bond, and then the encapsulation of ADD–DOX conjugates by DSPE-PEG2000 micelles with high drug encapsulation efficiency and well-controllable drug loading efficiency. The obtained ADD–DOX (M) micelles are found to be stable under physiological conditions, but can rapidly release drugs within acidic environments. Following cellular experiments confirm that ADD–DOX (M) vehicles can be internalized by MCF-7/ADR cancer cells through an endocytic pathway and exist within the moderate acidic endolysosomes, thus accelerating the hydrolysis of ADD–DOX and the release of free ADD and DOX. As a result, the ADD–DOX (M) formulation exhibits an excellent anti-MDR effect. In summary, we for the first time report the combinational use of ADD and DOX with an effective co-delivery strategy for the treatment of MDR cancer cells.

show abstract

Section: Resultssupporting

confidence: 91%

Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells

Cuixia

et al. 2015

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…480 The platinum(IV) prodrug VAAP (see Section 8) was encapsulated within the a poly(caprolactone)-PEG polymeric nanoparticle (Chart 23E). 362 The hydrophobic valproate axial ligands not only permit encapsulation, but upon reductive release are capable of acting as histone deacetylase inhibitors.…”

Section: Nanodelivery Of Platinum(iv) Complexesmentioning

confidence: 99%

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

2016

View full text Add to dashboard Cite

The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing non-classical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore non-classical platinum(II) complexes with trans geometry and with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-treat agents, and photoactivatable platinum(IV) complexes. Nanodelivery particles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also reflect our optimism that the next generation of platinum cancer drugs is about to arrive.

show abstract

“…The platform has also been applied for combinatorial cancer treatment. For example, doxorubicin-combretastatin 113 , doxorubicin-Elacridar, 114 and paclitaxel–cisplatin 115 combinations were shown to improve tumor inhibition in various cancer models. In addition, docetaxel was combined with 111 indium and 90 yttrium into the hybrid nanoparticle system, resulting in a class of ‘ChemoRad’ nanoparticles for the targeted delivery of concurrent chemoradiation.…”

Section: Core–shell Lipid–polymer Hybrid Nanoparticlesmentioning

confidence: 99%

Liposome-like nanostructures for drug delivery

et al. 2013

Self Cite

View full text Add to dashboard Cite

Liposomes are a class of well-established drug carriers that have found numerous therapeutic applications. The success of liposomes, together with recent advancements in nanotechnology, has motivated the development of various novel liposome-like nanostructures with improved drug delivery performance. These nanostructures can be categorized into five major varieties, namely: (1) polymer-stabilized liposomes, (2) nanoparticle-stabilized liposomes, (3) core-shell lipid-polymer hybrid nanoparticles, (4) natural membrane-derived vesicles, and (5) natural membrane coated nanoparticles. They have received significant attention and have become popular drug delivery platforms. Herein, we discuss the unique strengths of these liposome-like platforms in drug delivery, with a particular emphasis on how liposome-inspired novel designs have led to improved therapeutic efficacy, and review recent progress made by each platform in advancing healthcare.

show abstract

Nanoparticledrug delivery enhances the cytotoxicity of hydrophobic–hydrophilic drug conjugates

Cited by 71 publications

References 29 publications

Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells

Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells

The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

Liposome-like nanostructures for drug delivery

Contact Info

Product

Resources

About